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Introduction 
Psoriasis is a common chronic inflammatory skin disease characterized by 
hyperproliferative epidermis and mixed cutaneous lymphocytic infiltrate1 that occurs in 
genetically predisposed individuals. The disease affects 1-3% of the world’s 
population2; its onset is typically between 15 and 35 years. Psoriasis etiopathogenesis is 
still unknown, but evidences suggest that it is a complex disorder caused by the 
interaction among multiple genes, immune system, and environmental factors3. The 
dermatosis is considered to be a genetically programmed disease of dysregulated 
inflammation, which is driven and maintained by multiple components of the immune 
system3. Until relatively recently, psoriasis has been considered to be a mainly T helper 
(Th)1-driven inflammatory condition; however, several findings have now assessed a 
major role for Th17 cells in its pathogenesis 4,5. Many immune-derived cytokines, 
including interleukin (IL)-1, IL-6, IL-17, IL-19, IL-20, IL-22, tumour necrosis factor 
(TNF)-a and interferon (IFN)s, are over-expressed in psoriasis skin which may 
contribute to psoriatic skin inflammation and can also regulate keratinocyte proliferation. 
Moreover, the inflammatory cytokine milieu influences the immune functions of 
fibroblasts and endothelium, with the latter being critical for leucocyte trafficking and 
extravasation4. It has been demonstrated that keratinocytes synthesize and secrete many 
cytokines; some of these interact with many other skin cells3,6, particularly with 
melanocytes. Keratinocytes, melanocytes and dermal fibroblasts communicate with 
each other by secreted factors and by cell-cell contacts7. Melanocytes are specialized 
epidermal cells, originated from the neural crest, representing 2–5% of the cells in the 
epidermis5. These cells reside along the basal layer of epidermis, closely associated with 
both keratinocytes and Langerhans cells. They form the epidermal melanin units as a 
result of the relationship between one melanocyte and 30-40 associated keratinocytes. 
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The ratio of melanocytes to keratinocytes is 1:10 in the epidermal basal layer6 . They 
produce melanin by melanogenesis complex biochemical pathway. Synthesis and 
distribution of melanin in the epidermis depend on many phases: transcription of 
melanogenic proteins, melanosome biogenesis, sorting of melanogenic proteins into the 
melanosomes, transport of melanosomes to the tips of melanocyte dendrites and finally 
transfer into keratinocytes, where they form a melanin cap over the nuclei to protect 
DNA from ultraviolet (UV) damage 3,7-9. Two types of melanin are produced – 
pheomelanin and eumelanin 6. They differ in color and the way of synthesis; both are 
derived products of 3,4-dihydroxyphenylalanine (DOPA) and both are formed in 
melanosomes from tyrosine through a series of oxidative steps. The melanin synthesis 
requires the enzyme tyrosinase and tyrosinase-related proteins (TRP-1 and TRP-2) that 
catalyse the oxidation of tyrosine to L-DOPA7-9. These events are closely regulated by a 
variety of paracrine and autocrine factors in response to endogenous and exogenous 
influences, principally UV irradiation 3,6. Keratinocytes control melanocyte growth and 
activity through a system of paracrine growth factors and cell adhesion molecules10. The 
cross-talking of different signaling pathways between keratinocytes and melanocytes is 
a part of an epidermal complex network involved in the maintenance of skin 
homeostasis 6. Potent mitogens are growth factors and hormones as stem cell factor 
(SCF), hepatocyte growth factor (HGF), endothelins (ETs), α-melanocyte stimulating 
hormone (MSH), adrenocorticotropic hormone (ACTH) and many other inflammatory 
and growth mediators3. α-MSH and ACTH are potent stimulators of melanogenesis 
through proopiomelanocortin (POMC) precursor and derived peptides; ET-1 is also 
involved in the regulation of melanogenesis, through activation of tyrosinase, increasing 
TRP-1 levels and stimulatiing melanocyte proliferation and dendrite formation3,11,12. A 
major role is attributed to  microphthalmia-associated transcription factor (MITF) as the 
main melanocyte transcription factor influencing proliferation, dendrite formation, 
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melanin synthesis and inducing the expression of antiapoptotic genes; the MITF 
activates genes are responsible for the migration to the skin, preventing apoptosis in 
migrating cells, melanin production3,13. In addition, several keratinocyte-derived 
cytokines known to inhibit human melanogenesis have been identified; these include 
transforming growth factor-β (TGF-β), INF-β, IL-1, IL-6, TNF-α. Swope et al. first 
hypothesized and demonstrated that IL-1a, IL-6 and TNF-α epidermal cytokines may 
provide autocrine and paracrine regulatory inhibition signals for melanocytes. In fact, 
these cytokines could downregulate melanization and replication of melanocytes by a 
greater inhibitory effect on tyrosinase activity 3,14. They also decrease melanocyte 
proliferation, but are not toxic to the cells. However, the effect of these cytokines on 
tyrosinase expression, protein level, and stability is not well-known 15. Moreover, a 
hypopigmenting effect has been demonstrated for TGF-β using B16 ⁄F10 mouse 
melanoma cells as a model16. Members of the TGF-β family are also Bone 
Morphogenetic Proteins (BMPs)15. While originally identified as molecules that 
stimulate bone formation, it is now well recognized that BMPs signalling plays essential 
roles in the control of organ development, postnatal remodelling and regeneration by 
regulating proliferation, differentiation and apoptosis in many cell types 15-19. During 
skin development, BMPs control the initiation phase of hair follicle morphogenesis, as 
well as being required for a proper control of keratinocyte differentiation in epidermis 
15-19. Currently, BMPs family consists of more than 20 secreted proteins that share 
structural homology exerting their biologic activity after interaction with specific BMP 
receptors 15,20. Particularly, it was discovered that BMP-2 and BMP-4 have a prominent 
function in melanogenesis development. Bilodeau  et al demonstrated that BMP-2 
treatment of neural crest cells increases melanogenesis by promoting the synthesis of 
melanin rising the expression of tyrosinase gene; moreover, BMP-2 exerts no effect on 
the expression of the TRP-1 and TRP-2 or MITF, supporting the fact that BMP-2 does 
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not affect melanocyte differentiation 21. Normal neonatal human melanocytes and 
keratinocytes express BMP-4. BMP-4 leads to decreased tyrosinase mRNA, decreasing 
message stability, repressing tyrosinase promoter activity, reducing tyrosinase protein 
and tyrosinase activity and melanin levels 17. 
Several evidences suggest that BMPs play a part in psoriasis pathophysiology. Long-
term treatment of C57BL/6 mice with BMP-2 or BMP-4 result in thickening of the 
epidermis with development of psoriasis-like lesions. Moreover, elevated BMP 
signaling may stimulate angiogenesis because of up-regulation of vascular endothelial 
growth factor synthesis. Although the BMP role in psoriasis development remains to be 
determined 15. 
The possible immunological interaction between psoriasis and melanogenesis is 
particularly interesting for clinical and therapeutic implications. There is some evidence 
that immunosuppressive therapy is associated with the development of eruptive benign 
melanocytic naevi and acquired dermal melanocytosis 22–25. Moreover, Balato et al. 
showed that psoriatic subjects have a smaller number of melanocytic naevi, including 
atypical ones probably because the proinflammatory cytokine network in psoriasis skin 
might inhibit melanogenesis, melanocyte growth and ⁄or progression to naevi 3.  
Aim of our study was to investigate possible differences in melanogenesis markers 
between psoriatic and healthy skin. 
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Materials and Methods 
Study population 
The  overall study enrolment comprised 20 caucasian patients with moderate to severe 
psoriasis, without arthritis (mean age 41.2; range 18-50 years) as well as 20 aged-
matched healthy controls (mean age 39.7 range 18-47 years).  The study was conducted 
according to the Declaration of Helsinki principles. The local ethical committee 
approved the study, and each participant gave written informed consent before entering 
the study. Controls comprised healthy donors who had undergone to plastic surgery. All 
subjects undergoing treatment with immunosuppressant therapy including systemic 
corticosteroids, ciclosporin, methotrexate, psoralen plus UVA (PUVA) therapy and 
biologic drugs, patients affected by other inﬂammatory skin diseases (including obesity), 
or patients who had already received a diagnosis of atypical melanocytic naevi, were 
excluded. In both study groups, the number of melanocytic naevi, deﬁned as all well-
circumscribed brown ﬂat or raised lesions with a distinct border and a diameter of 2 mm 
or larger (measured by over-laying a 2-mm stencil of a circle), was registered using two 
ranges (< 5 naevi; > 50 naevi), for each range 10 patients and 10 healthy controls were 
enrolled.  
In vivo expression of Tyrosinase, MITF and BMPs members family in Psoriatic 
Skin and Healthy Skin  
Skin punch biopsies (3mm diameter, location: trunk)  were obtained from control group 
as well as psoriatic group (lesional and non lesional skin) and used for in vivo mRNA 
examination  through real-time polymerase chain reaction (qRT-PCR). 
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Immunoistochemical detection of Tyrosinase and BMP-4 in Psoriatic Skin and 
Healthy Skin  
Immunoistochemical detection of Tyrosinase and BMP-4 was carried out on the skin 
biopsies from the psoriatic skin before and after 16 weeks treatment with adalimumab 
(administered in according to drug bulletin) and healthy skin. Skin samples were 
immediately placed in tissue freezing medium (Jung,  Leica, Wetzlar, Germany)  and 
stored at −80°C. Five micrometer sections were cut with a cryostat and Vectastain Elite 
ABC Kit (Vector  Laboratories, Burlingame, CA) was used as follows: sections were 
incubated with blocking solution (horse serum diluted in buffer: phosphate buffered 
saline PBS + bovine serum albumin 1%) for 20 min at 22°C. Biopsies were stained with 
anti-tyrosinase(1 µg/ml, GIBCO, Grand  Island, NY ), BMP-4 (10 µg/ml Fitzgerald, 
Sudbury, USA) and incubated overnight at 4° C. In parallel, skin specimens were 
incubated with specific isotype control antibodies (Mouse IgG1 Isotype Control, Mouse 
IgG2B Isotype Control, Goat IgG Control, R&D System Inc, Minneapolis, MN) used at 
the same concentration as the corresponding primary antibody. The sections were then 
washed in buffer and incubated with biotinylated secondary antibody for 30 min at 
room  temperature. Peroxydase activity was revealed using DAB substrate (ImmPACT 
DAB, Burlingame, CA). Counterstaining was performed with hematoxylin. Staining 
was observed using Nikon Eclipse E600 epifluorescence microscope (Nikon, Melville, 
NY).  
Melanin Content Assay in Psoriatic Skin and Healthy Skin 
Total cellular melanin content was performed in healthy skin and in psoriatic skin 
biopsies before and after 16 weeks treatment with adalimumab using Fontana-Masson 
staining (AMTS Inc., Lodi, CA, USA), according to the manufacturer’s instructions. 
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Ex vivo full-thickness skin organ cultures 
Skin specimens from healthy donors were cultured as  follows: a hole was punched  in a  
transwell  filter  (pore  size 1 µm; Beckton Dickinson Labware, Franklin Lakes, NJ). 
The biopsy was  inserted  into the hole, and  the filter containing  the biopsy  was  
placed  in  a  12-well  culture  plate  (Beckton  Dickinson  Labware)  with Dulbecco’s 
modified Eagle’s medium  (DMEM, GIBCO, Grand  Island, NY) containing 10% FBS 
(GIBCO),  2  mM  L-glutamine  (GIBCO)  and  antibiotics  (100  IU/ml  penicillin  G,  
100  µg/ml streptomycin, GIBCO).  In  this  system  the epidermis faces upwards at  the  
liquid-air  interface whereas  the  dermis  is  suspended  in  the  culture medium. The  
tissue was  incubated  at 37° C in  a humidified atmosphere containing 5% CO2. Healthy 
skin biopsies were stimulated with TNF-α (GIBCO), at 20 ng/ml for 24 hrs. 
Normal human epidermal sheets 
Normal human epidermal sheets were isolated from healthy donors as previously 
described 26. Epidermal sheets were cultured as described for ex vivo full-thickness skin 
organ cultures and stimulated with TNF-α (GIBCO) at 20ng/ml for 24 hours. 
RNA extraction, cDNA synthesis and qRT-PCR 
 RNA was extracted from every skin specimen (RNeasy Mini Protocol, Qiagen 
Valencia, CA)  and  cDNA was  prepared  (Transcriptor High  Fidelity  cDNA  
Synthesis, Roche,  Indianapolis, IN) according  to  the manufacturer’s  instructions. 
PCR (LightCycler, Roche, Indianapolis, IN) was used  to analyze  the  levels of 
expression of 18S,  Tyrosinase, MITF, BMP-2, BMP-4, BMP-6, BMP-7. Each PCR was 
performed 2 times, each time in triplicate. PCR protocol and product quantification for 
18S ribosomal RNA were performed as reported previously 27. PCR primers for the 
selected genes were designed based on published sequences, and  their specificity was 
verified with BLAST alignment search. To confirm amplification of  the expected size 
fragment, amplification products were characterized by agarose gel electrophoresis. 
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Melting curve analysis was carried out after completion to confirm the presence of 
single amplified species. The amount of mRNA for a given gene in each sample was 
normalized to  the  amount  of  mRNA  of  18S  reference  gene  in  the  same  sample.  
Fold  induction  of  gene expression was calculated using  the CT method as described 
previously 28. Results obtained  from each PCR were pooled and statistically analyzed. 
to  the  amount  of  mRNA  of  18S  reference  gene  in  the  same  sample.  Fold  
induction  of  gene expression was calculated using  the ∆∆CT method as described 
previously 27. Results obtained from each PCR were pooled and statistically analyzed.   
Immunogold staining in Psoriatic Skin and Healthy Skin 
Tissue samples were fixed in a mixture of 0.5% glutaraldehyde and 2% 
paraformaldehyde in PBS  overnight at 4°C and washed in the same buffer. Following 
dehydration, samples were embedded in Epon resin, and ultrathin sections (60 nm) were 
collected on 200 mesh nickel grids. Samples were washed three times in distilled water 
for 5 min, equilibrated in PBS containing 1.5% goat serum and 1% BSA for 15 min and 
incubated overnight at 4 °C with anti-tyrosinase(1 µg/ml, GIBCO, Grand  Island, NY ), 
BMP-4 (10 µg/ml Fitzgerald, Sudbury, USA) diluted in PBS/BSA 1%. Following five 
2-min washings in PBS and five washings in PBS/BSA 0.5%, sections were incubated 
in 1% PBS/BSA for 15 min and then for 1 h at room temperature with the goat anti-
mouse secondary antibody (H & L) labeled with 20-nm gold particles (BBInternational, 
Cardiff, United Kingdom). Sequential washings were performed in 1% PBS/BSA for 15 
min, in 0.5% PBS/BSA five times for 2 min, in PBS five times for 2 min, and in 
distilled water twice for 1 min. After staining with uranyl acetate, sections were 
analyzed using a Leo 912AB electron microscope (Carl Zeiss, Jena, Germany). Controls, 
based on the use of only secondary antibody, were run in parallel. 
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Detection of Serum Levels of BMP-4  
Blood from patients and controls was obtained by venepuncture and collected in sterile 
heparinized glass vials and  blood samples were centrifuged and the serum was 
collected and frozen at -80°C until analysis. Serum BMP-4 levels were determined 
using sandwich ELISA kits (Sigma, St Louis,. MO, USA), according to the 
manufacturer’s instructions. 
Statistical analyses 
All statistical analyses were performed using GraphPad Prism 4.0 (GraphPad Software 
Inc, La Jolla, CA). Student’s t test or Mann-Whitney test were used to calculate 
statistical differences. Analysis of biopsies from lesional vs non lesional psoriatic skin 
was performed with Wilcoxon matched pairs test. Values of p < 0.05 were considered 
significant and all data are displayed as means ± SD. 
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Results 
In vivo expression of Tyrosinase and MITF in Psoriatic Skin and Healthy Skin  
We examined the constitutive expression of Tyrosinase and MITF using qRT-PCR in 
lesional skin of psoriatic patients with respectively <5 naevi and >50 naevi; in non-
lesional skin of these same patients and in healthy skin, matching <5 naevi and >50 
naevi. The expression of Tyrosinase and MITF was significantly decreased in psoriatic 
skin respect to related non-lesional skin and healthy skin, without differences between 
skin from people with <5 naevi and > 50 naevi. Moreover, the relative expression of 
these melanogenesis factors did not differ in non-lesional skin from control skin 
 (Figure 1). 
In vivo expression of BMP family members in Psoriatic Skin and Healthy Skin  
The recent identification of BMP members family in melanogenesis prompted us to 
investigate their involvement in psoriasis. Thus, we examined the constitutive expression of 
BMP-2, BMP-4, BMP-6 and BMP-7 using qRT-PCR in lesional skin of psoriatic patients 
with respectively <5 naevi and >50 naevi; in non-lesional skin of these same patients 
and in skin from normal donors, matching <5 naevi and >50 naevi. The expression of 
BMP-2, BMP-6 and BMP-7 did not show differences between examined  groups; only 
BMP-4 presented a significant reduction in psoriatic skin versus corresponding non-
lesional skin and healthy skin, without differences relative to <5 naevi and > 50 naevi 
skin and non-lesional skin from control skin (Figure 2). 
Immunohistochemical detection of Tyrosinase and BMP-4 in Psoriatic Skin and 
Healthy Skin  
To confirm qRT-PCR data, we also evaluated the immunohistochemical expression of  
Tyrosinase and BMP-4 in healthy skin, in psoriatic lesional and non-lesional skin. 
Moreover, in order to evaluate the relationship between anti-TNF-α treatment and 
melanogenesis factors,  immunohistochemical detection of Tyrosinase and BMP-4 was 
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conducted in lesional and non-lesional psoriatic skin after 16 weeks of treatment with 
adalimumab.  
Staining for Tyrosinase and BMP-4 showed a substantially lower intensity in psoriatic 
skin compared with normal skin. Non-lesional skin of psoriatic patients and normal skin 
presented similar intensity of staining (data not shown). Immunohistochemical detection 
of both Tyrosinase and BMP-4 in lesional and non-lesional (data not shown) psoriatic 
skin after adalimumab treatment registered analogous staining strength respect to 
normal skin. Immunohistochemical staining intensities of analyzed melanogenesis markers 
confirmed the results above reported (Figures 3, 4).  
Melanin content assay in Psoriatic Skin and Healthy Skin 
To corroborate immunohistochemical detections, we performed a histological 
visualization of melanin content, using the Fontana-Masson Stain Kit in healthy skin, in 
lesional and non-lesional psoriatic skin before and after anti-TNF-α treatment. Lesional 
skin contained dramatically a poor content of melanin compared to healthy skin and 
non-lesional skin (data not shown).  Whereas, normal skin and non-lesional psoriatic 
(data not shown) skin presented the same staining levels like as psoriatic skin after 
adalimumab treatment (Figures 5).   
Expression of Tyrosinase and BMP-4 in ex vivo full-thickness skin organ cultures  
Given the down-regulation of Tyrosinase and BMP-4 in psoriatic skin, and the 
preminent role of anti-TNF-α treatment as condition that can be assimilated to non 
lesional skin and healthy skin, we sought to examine whether TNF-α regulate 
melanogenesis markers in ex vivo skin organ culture. qRT-PCR revealed that TNF-α 
significantly decreased Tyrosinase and BMP-4 mRNA expression, compared to 
untreated skin (Figure 6).  
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Expression of Tyrosinase and BMP-4 in ex vivo human epidermal sheet  
In order to evaluate if the epidermis was involved in this decrement, we treated normal 
human epidermal sheet with TNF-α and then analyzed Tyrosinase and BMP-4 mRNA 
levels. qRT-PCR revealed that TNF-α significantly reduced tyrosinase and BMP-4 
mRNA expression compared to untreated normal human epidermal sheet (Figure 7). 
Detection of Serum Levels of BMP-4 
Serum levels of BMP-4 were measured using ELISA assay in psoriatic subjects as well 
as healthy controls. Our findings showed that BMP-4 was increased in psoriatic patients 
respect to healthy individuals (Figure 8). 
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Discussion 
The present work intended to evaluate the potential differences relative to 
melanogenesis markers between healthy and psoriatic skin. Immunological interactions 
among psoriasis and melanogenesis may probably be related to the reflection that some 
cytokines, involved in psoriasis pathogenesis, have a role in melanogenesis pathway 3. 
In particular, IL-1a, IL-6, IL-17,TNF-A and TGF-β may inhibit melanogenesis and 
melanocytic growth because of their inhibitory effects on tyrosinase activity; the 
identical cytokines are implicated in the up-regulation of keratinocyte proliferation in 
the pathogenesis of psoriasis 1,3, 14, 29-33. On these basis, we sought and demonstrated 
previously that psoriatic subjects showed a smaller number of melanocytic naevi, 
including atypical ones 3 and, after us, Di Cesare at al recorded a fewer number of 
melanocitic lesions in psoriatic subjects 34 .  
In the actual study, we examined in depth some of more relevant pro-melanogenesis and 
anti-melanogenesis factors  in healthy and psoriatic skin. 
First,  we analyzed skin biopsy specimens obtained from psoriasis lesional and non-
lesional skin and found that expression of Tyrosinase and MITF was significantly 
decreased in psoriatic skin respect to related non-lesional skin and healthy skin. 
Moreover, the relative expression of these melanogenesis factors was similar in non-
lesional skin versus control skin. These results were extended and confirmed at proteic 
level by immunohistochemical examination of biopsies. In addition, our results were 
reinforced by histological visualization of a dramatically poor content of melanin in 
psoriatic lesional skin compared to healthy skin and non-lesional psoriatic skin. 
Moreover, since it is described outbreaks of eruptive benign melanocytic naevi during 
immunosuppressive therapy (including anti-TNF-α treatment for psoriasis) 23, we 
required to evaluate the relationship between an anti-TNF-α drug (adalimumab) 
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treatment and these melanogenesis markers, using immunohistochemical and melanin 
staining detection. We registered that adalimumab treatment, in both lesional and non-
lesional skin, presented similar immunohistochemical staining and similar melanin 
content of normal skin. The most plausible speculation to give an explication for this 
observation may be that adalimumab therapy permit a recovery to an intact 
immunological status and it prompt to reduce cytokines that normally inhibits the 
proliferation of melanocytic lesions in psoriatic skin. After all, our data partially agree 
with a recent work of Wang et al.33 ; they revealed a significant decrease in Tyrosinase 
and MITF levels in melanocytes after 48h exposure to IL-17 and TNF-α synergistically, 
but contrary to us they detected unexpected reduction of cellular melanin content in 
psoriasis skin. As well as us, they recognized an increased number of melanocytes, 
combined with a rapid recovery of pigmentation function during psoriasis resolution, in 
the majority of patients treated with etanercept. They ascribed this observation to an 
abundant production of melanin during treatment due to post-inflammatory hyper-
pigmentation after psoriasis resolution 33. We speculate that the reduction of Tyrosinase 
in psoriatic skin respect to non-lesional skin and healthy skin and the upturn of 
Tyrosinase in lesional and non-lesional skin after adalimumab treatment could reveal 
the fact that the local citokines re-balance pile out also in the keratinocyte-melanocyte 
cross talking. These data were also emphasized using ex vivo full-thickness skin organ 
cultures and in ex vivo human epidermal sheet stimulated with TNF-α. 
In this study, we also analyzed the role of BMPs members family in psoriasis. The 
expression of BMP-2, BMP-6 and BMP-7 did not evidence differences between 
examined groups; only BMP-4 expression significantly was reduced in psoriatic skin 
versus corresponding non-lesional skin and healthy skin, without differences relative to 
<5 naevi and > 50 naevi skin and without discrepancies among non-lesional skin from 
control skin. This result was confirmed at proteic level,  through immunhistochemistry 
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and histological visualization of melanin, and in vitro, using ex vivo full-thickness skin 
organ cultures and human epidermal sheet stimulated with TNF-α.  
Given data previously reported in the literature 3, 33, 34, the observed tendency to 
reduction of Tyrosinase and MITF was expected; but the decreasing of BMP-4 in 
psoriatic skin was not estimated. This decrement was not confirmed at serum level, 
using ELISA, because BMP-4 serum level was increased in psoriatic patients respect to 
healthy individuals.  
The activities of BMPs are precisely regulated by certain classes of molecules that are 
recently recognized as BMPs antagonists that prevent BMP binding to BMP receptors 
35, 36 . BMPs activity in developing and in adult tissues is modulated and antagonized on 
different levels (extracellular, cytoplasmic, and nuclear). All antagonist proteins bind 
members of the BMP family with higher affinity than the BMPR complex, thus 
restricting BMP activity to the tissue compartments.  Also, some BMP antagonists are 
able to bind simultaneously BMP and other growth factors and institute a balance of 
growth regulators in specific tissue, including skin during  hyperproliferative disorders 
15, 35. The detection of higher BMP-4 serum level in psoriatic subjects respect to healthy 
controls let us to speculate that BMP-4 could sustain inflammation systemic status in 
psoriatic patients as well as atherosclerosis or metabolic syndrome 37-40.  
Moreover, it is recognized that BMPs stimulate angiogenesis, key pathogenic feature of 
psoriasis 41, through VEGF-independent pathways via indirect or direct effects on 
endothelial cells, as is shown in osteoblasts 15,42-44.  
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Conclusions 
Our study evidenced differences between Tyrosinase and MITF, master regulators taken 
part in activation of melanogensis pathway, among healthy and psoriasis skin. In 
particularly, these data showed a possible involvement of Tyrosinase in 
“hyperpigmentation” post anti-TNF-α therapy. 
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Figures and Legends 
 
Figure 1: In vivo expression of Tyrosinase and MITF in Psoriatic Skin and 
Healthy Skin 
The expression of Tyrosinase and MITF was significantly reduced in psoriatic 
skin respect to related non-lesional skin and healthy skin, without differences 
between skin from people with <5 naevi and > 50 naevi. Moreover, the relative 
expression of these melanogenesis factors did not differ in non-lesional skin 
from control skin. (* p<0.1) 
HS: Healthy Skin; NL: Non Lesional psoriatic skin; L: Lesional psoriatic skin 
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Figure 2: In vivo expression of BMP family members in Psoriatic Skin and 
Healthy Skin 
The expression of BMP-2, BMP-6 and BMP-7 did not show differences between 
examined  groups; only BMP-4 presented a significant reduction in psoriatic 
skin versus corresponding non-lesional skin and healthy skin, without 
differences relative to <5 naevi and > 50 naevi skin and non-lesional skin from 
control skin. (* p<0.1) 
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Figure 3: Immunohistochemical detection of Tyrosinase in Psoriatic Skin and 
Healthy Skin 
Staining for Tyrosinase showed a substantially lower intensity in psoriatic skin (a; 
a1) compared with normal skin (c). Immunohistochemical detection of Tyrosinase 
in lesional psoriatic skin after adalimumab treatment (b) registered analogous 
staining strength respect to normal skin (20x magnification; 40x magnification). 
HS: Healthy Skin; L: Lesional psoriatic skin 
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Figure 4: Immunohistochemical detection of BMP-4 in Psoriatic Skin and 
Healthy Skin 
Staining for BMP-4 showed a lower intensity in psoriatic skin (a; a1) respect to 
normal skin (c). Immunohistochemical detection of BMP-4 in lesional psoriatic skin 
after adalimumab treatment (b) registered similar staining potency in comparison to 
normal skin (20x magnification; 40x magnification). 
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Figure 5: Melanin content assay in Psoriatic Skin and Healthy Skin 
Histological visualization of melanin content showed that lesional skin (a, a1) 
contained dramatically a poor content of melanin compared to healthy skin (c) and 
psoriatic skin after adalimumab treatment (b).  Moreover normal skin (c) and skin 
after adalimumab treatment (b) presented the same staining levels (20x 
magnification; 40x magnification). 
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Figure 7:  Expression of Tyrosinase and BMP-4 in ex vivo full-thickness 
skin organ cultures.  
In ex vivo skin organ culture stimulated with TNF-α, Tyrosinase and BMP-4 
mRNA expression significantly decreased, compared to untreated skin. (p<0.1) 
 
Figure 8: Expression of Tyrosinase and BMP-4 in ex vivo human epidermal 
sheet  
In normal human epidermal sheet treated with TNF-α Tyrosinase and BMP-4 
mRNA levels were reduced compared to untreated normal human epidermal 
sheet. (* p<0.1) 
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Figure 9: Detection of Serum Levels of BMP-4 
BMP-4 serum level was increased in psoriatic patients respect to healthy 
individuals. (** p<0.01)
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